SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

The Dogecoin community is abuzz with speculation over its potential integration into Elon Musk's X platform for payments, driving fervent hopes for a significant rally while others caution against market volatility.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is experiencing strong upward momentum, with the crypto community enthusiastically discussing a "meme coin season" and its potential for significant gains, often framing it as the "alpha frog" in a broader "three frog narrative."

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid a broader crypto market rebound, with the community actively speculating whether a new "meme coin season" is underway, prompting discussions about potential gains for SHIB and other meme tokens.

The KARATE token is the official digital currency in the KarateDAO and it gives fans the power to vote to support their favorite fighters, vote on upcoming fights, take part in prize pools, and join exclusive events via Karate Combat's Up Only Gaming App.

Karate Combat

Karate Combat (KARATE CRYPTO) is trending as a unique Web3 combat sports league, sparking community discussion around its immersive live fights, gamified fan engagement, and the upcoming launch of its Hedera-based UP Layer-2 blockchain and $UP token. Investors are keenly watching its growth potential and strategic partnerships, positioning it as a 'gem' for the anticipated altcoin season.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron (TRX) is trending due to its strong ties to Tether for stablecoin transfers and a significant partnership with Rumble for cloud services and crypto payments to creators. Community discussions highlight its continued utility for low-cost transactions and expanding ecosystem, amidst ongoing conversations about regulatory developments and its position in the stablecoin market.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Saakuru

Despite confusion around its ticker identity on some platforms, the crypto community is actively discussing a token, widely believed to be the "Seeker Solana Smartphone Token," following its new listings on major exchanges and recent airdrops to Solana phone owners. This asset is experiencing significant momentum, drawing comparisons to past Solana ecosystem pumps, while some caution about potential profit-taking and volatility.

Tether (USDT) is a cryptocurrency with a value meant to mirror the value of the U.S. dollar. The idea was to create a stable cryptocurrency that can be used like digital dollars. Coins that serve this purpose of being a stable dollar substitute are called “stable coins.” Tether is the most popular stable coin and even acts as a dollar replacement on many popular exchanges! According to their site, Tether converts cash into digital currency, to anchor or “tether” the value of the coin to the price of national currencies like the US dollar, the Euro, and the Yen. Like other cryptos it uses blockchain. Unlike other cryptos, it is [according to the official Tether site] “100% backed by USD” (USD is held in reserve). The primary use of Tether is that it offers some stability to the otherwise volatile crypto space and offers liquidity to exchanges who can’t deal in dollars and with banks (for example to the sometimes controversial but leading exchange Bitfinex)  The digital coins are issued by a company called Tether Limited that is governed by the laws of the British Virgin Islands, according to the legal part of its website. It is incorporated in Hong Kong. It has emerged that Jan Ludovicus van der Velde is the CEO of cryptocurrency exchange Bitfinex, which has been accused of being involved in the price manipulation of bitcoin, as well as tether. Many people trading on exchanges, including Bitfinex, will use tether to buy other cryptocurrencies like bitcoin. Tether Limited argues that using this method to buy virtual currencies allows users to move fiat in and out of an exchange more quickly and cheaply. Also, exchanges typically have rocky relationships with banks, and using Tether is a way to circumvent that.  USDT is fairly simple to use. Once on exchanges like Poloniex or Bittrex, it can be used to purchase Bitcoin and other cryptocurrencies. It can be easily transferred from an exchange to any Omni Layer enabled wallet. Tether has no transaction fees, although external wallets and exchanges may charge one. In order to convert USDT to USD and vise versa through the Tether.to Platform, users must pay a small fee. Buying and selling Tether for Bitcoin can be done through a variety of exchanges like the ones mentioned previously or through the Tether.to platform, which also allows the conversion between USD to and from your bank account.

Tether

Tether is trending amid intense community discussion over its expanding strategic investments and significant ownership in companies like Rumble, alongside renewed debate on the stablecoin's asset backing and market influence following a recent S&P Global downgrade.

BlockDAG

BlockDAG is trending as its community grapples with continuous, often conflicting, announcements regarding its mainnet launch and exchange listings, leading to widespread speculation and frustration over perceived delays, lost coins, and concerns about the project's overall legitimacy as a presale.

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

Upstream Bio is trending due to a significant market sell-off following its Phase 2 VALIANT trial results for verekitug in severe asthma. Although the drug showed strong efficacy with quarterly dosing, the community is debating an 'overreaction' because the highly anticipated biannual dosing did not meet market expectations, with many investors now viewing it as a dip-buying opportunity.

BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF

iShares Biotechnology ETF

A wave of M&A activity is driving significant conversation around the iShares Biotechnology ETF, with community members highlighting numerous undervalued companies poised for potential acquisitions and speculating on a broader resurgence for the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company outlined progress on its anticoagulation pipeline, including its HIT program VLX-1005, at a Lytham Partners investor summit.</li><li>Cadrenal said VLX-1005 has completed a Phase 2 trial, with data under review and FDA discussions planned.</li><li>Shares fell 4% on Friday before ticking higher after the close.</li></ul>Cadrenal Therapeutics drew renewed retail investor interest on Tuesday after&nbsp;the biotech company&nbsp;outlined progress across its anticoagulation pipeline, VLX-1005,&nbsp; which it&nbsp;acquired from Veralox Therapeutics in December.At a&nbsp;fireside chat at the Lytham Partners Healthcare Investor Summit,&nbsp;Cadrenal CEO Quang Pham and acting Chief Scientific Officer Matt Boxer described how the asset fits into the company’s broader strategy to address gaps left by long-standing anticoagulants such as Warfarin and Heparin, as well as newer direct oral anticoagulants (DOACs).The stock fell 4% to close at $7.87 on Friday, before edging up 0.8% in after-hours trading.<h2 class="st-heading-2">Targeting A High-Risk Complication Of Heparin Use</h2>VLX-1005 is being developed for heparin-induced thrombocytopenia, or HIT, a condition caused by an immune reaction to heparin. Boxer said patients exposed to heparin can develop antibodies that form complexes with platelet factor 4.This process leads to platelet consumption while simultaneously triggering clot formation, he said. As a result, patients can develop thrombosis and ischemia, with cases sometimes progressing to amputations, organ failure, and death, even though they were initially given heparin for anticoagulation.Boxer said existing treatments mainly work by inhibiting the clotting cascade, a strategy that can increase bleeding risk in patients with already low platelet counts. He added that about 50,000 confirmed new HIT cases occur each year in the U.S., driven in part by the continued use of heparin in cardiovascular surgery, with cases also seen globally.<h2 class="st-heading-2">Phase 2 Data And Next Steps</h2>VLX-1005 was designed to act earlier in the disease process by blocking 12-lipoxygenase (12-LOX), an enzyme that plays a role in triggering immune-driven platelet activation.&nbsp;The program has completed a Phase 2 clinical trial, with the database locked and data currently under analysis. Pham said the company has been engaging with primary investigators through introductions made by the Veralox team and expects the data to be published in the near term.VLX-1005 has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). Pham said work on chemistry, manufacturing and controls is underway, with discussions with the FDA expected later this quarter.<h2 class="st-heading-2">Other Programs In Development</h2>Alongside VLX-1005, Cadrenal is advancing Tecarfarin, a vitamin K antagonist designed to be more kidney-friendly, for patients with end-stage kidney disease and atrial fibrillation, as well as those with implanted mechanical heart valves and left ventricular assist devices. Tecarfarin holds orphan drug designations for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), as well as for those with left ventricular assist devices (LVADs).Pham also referenced Fruinexian, a short-acting Factor XI candidate acquired in late 2025 for use in cardiovascular surgery, noting broader industry interest in Factor XI inhibitors as the company awaits the first approvals in the class.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Cadrenal was ‘neutral’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cvkd_ss_png_379707bd48.webp" alt="cvkd ss.png" width="969" height="140"><figcaption>CVKD sentiment and message volume as of January 19 | Source: Stocktwits</figcaption></figure>One user said, “<a href="https://stocktwits.com/symbol/CVKD">$CVKD</a> is showing early strength.”<stembedurl>https://stocktwits.com/JoannMotta/message/642239634</stembedurl>&nbsp;Another user described the stock’s current levels as a zone to keep&nbsp;an eye on.<stembedurl>https://stocktwits.com/LydiaBoyce/message/642238255</stembedurl><a href="https://stocktwits.com/symbol/CVKD">Cadrenal’s stock</a> has declined 57% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Cadrenal Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Equity

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$5.54
Prev Close	$5.42
Open	$5.42
Dividend Yield	0.00%
50-Day Moving Average	$7.75
Beta	0.77
Avg. Volume	54,827.80
PE Ratio	-0.69

52-Week High	$22.90
52-Week Low	$5.34
Market Capitalization	$12.94M
EPS (Annual)	-$8.73
Price to Book	4.17
Revenue Per Employee	$0.00

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CVKD News

CVKDCadrenal Therapeutics, Inc.